GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocon Ltd (NSE:BIOCON) » Definitions » Cyclically Adjusted PB Ratio

Biocon (NSE:BIOCON) Cyclically Adjusted PB Ratio : 4.38 (As of Jun. 06, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Biocon Cyclically Adjusted PB Ratio?

As of today (2024-06-06), Biocon's current share price is ₹305.25. Biocon's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was ₹69.69. Biocon's Cyclically Adjusted PB Ratio for today is 4.38.

The historical rank and industry rank for Biocon's Cyclically Adjusted PB Ratio or its related term are showing as below:

NSE:BIOCON' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.49   Med: 7.07   Max: 11.46
Current: 4.44

During the past years, Biocon's highest Cyclically Adjusted PB Ratio was 11.46. The lowest was 3.49. And the median was 7.07.

NSE:BIOCON's Cyclically Adjusted PB Ratio is ranked worse than
76.7% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs NSE:BIOCON: 4.44

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biocon's adjusted book value per share data for the three months ended in Mar. 2024 was ₹165.305. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹69.69 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biocon Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Biocon's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocon Cyclically Adjusted PB Ratio Chart

Biocon Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 9.28 6.79 3.60 3.79

Biocon Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.60 - 4.26 - 3.79

Competitive Comparison of Biocon's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Biocon's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocon's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocon's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biocon's Cyclically Adjusted PB Ratio falls into.



Biocon Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biocon's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=305.25/69.69
=4.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocon's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biocon's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=165.305/153.0345*153.0345
=165.305

Current CPI (Mar. 2024) = 153.0345.

Biocon Quarterly Data

Book Value per Share CPI Adj_Book
201406 26.117 94.103 42.473
201409 26.843 96.780 42.446
201412 27.450 96.780 43.405
201503 27.185 97.163 42.817
201506 28.317 99.841 43.404
201509 30.216 101.753 45.444
201512 31.175 102.901 46.364
201603 33.615 102.518 50.179
201606 0.000 105.961 0.000
201609 36.841 105.961 53.208
201612 38.567 105.196 56.106
201703 40.314 105.196 58.647
201706 41.002 107.109 58.583
201709 41.161 109.021 57.778
201712 42.193 109.404 59.020
201803 43.173 109.786 60.180
201806 0.000 111.317 0.000
201809 47.530 115.142 63.172
201812 49.383 115.142 65.635
201903 50.817 118.202 65.792
201906 0.000 120.880 0.000
201909 53.171 123.175 66.060
201912 0.000 126.235 0.000
202003 55.882 124.705 68.577
202006 0.000 127.000 0.000
202009 58.788 130.118 69.142
202012 0.000 130.889 0.000
202103 63.558 131.771 73.814
202106 0.000 134.084 0.000
202109 65.698 135.847 74.010
202112 0.000 138.161 0.000
202203 70.678 138.822 77.914
202206 0.000 142.347 0.000
202209 80.698 144.661 85.369
202212 0.000 145.763 0.000
202303 149.640 146.865 155.926
202306 0.000 150.280 0.000
202309 158.732 151.492 160.348
202312 0.000 152.924 0.000
202403 165.305 153.035 165.305

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biocon  (NSE:BIOCON) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biocon Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Biocon's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocon (NSE:BIOCON) Business Description

Industry
Traded in Other Exchanges
Address
20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560 100
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Generics, Biosimilars, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene.

Biocon (NSE:BIOCON) Headlines

No Headlines